Featured Research

from universities, journals, and other organizations

Tuberculosis: Patients Face Difficulties With Ongoing Treatments

Date:
July 27, 2007
Source:
Public Library of Science
Summary:
Tuberculosis (TB) is a major killer, causing up to two million deaths worldwide every year. Treatment takes many months and many patients fail to complete the course of drugs prescribed. Now a study casts new light on the difficulties patients face in trying to stick to the treatment they are given.

Tuberculosis (TB) is a major killer, causing up to two million deaths worldwide every year. Treatment takes many months and many patients fail to complete the course of drugs prescribed. Now a study published in PLoS Medicine casts new light on the difficulties patients face in trying to stick to the treatment they are given.

Salla Munro of the South African Medical Research Council, with colleagues in South Africa, Norway and the UK, conducted a systematic review of research into adherence to TB treatment that has been carried out using 'qualitative' methods. In other words, they searched the medical literature for studies where patients and their families had been asked to say how they felt about their treatment. (This is different from 'quantitative' research where numbers are collected, rather than recording what patients actually say.)

The researchers found 44 qualitative studies on TB treatment that met their prespecified criteria. From a careful appraisal of these studies they were able to classify the major factors associated with difficulties in completing treatment. They conclude that adherence to treatment is influenced by: structural factors (including poverty and gender discrimination), social context factors, health service factors and personal factors (including attitudes towards treatment and illness).

From this research, it is clear that patients often take their TB medications under very difficult conditions and that they cannot control many of the factors that prevent them from taking their drugs. So, although current efforts to improve adherence to tuberculosis treatments emphasize instilling into patients a willingness to take their medications, this new study suggests that more must be done to address how factors such as poverty and gender affect treatment adherence and to tailor support systems to patients' needs.

Most importantly, it indicates that future interventions should involve patients far more in the decisions made about their treatment. As Salla Munro of the Medical Research Council notes: "Adherence to treatment is a complex phenomenon. We need more patient-centred interventions, and more attention to structural barriers, to improve treatment adherence and reduce the global disease burden of tuberculosis."

Citation: Munro SA, Lewin SA, Smith H, Engel ME, Fretheim A, et al. (2007) Patient adherence to tuberculosis treatment: A systematic review of qualitative research. PLoS Med 4(7): e238.

Further Information: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0040238


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Cite This Page:

Public Library of Science. "Tuberculosis: Patients Face Difficulties With Ongoing Treatments." ScienceDaily. ScienceDaily, 27 July 2007. <www.sciencedaily.com/releases/2007/07/070724113949.htm>.
Public Library of Science. (2007, July 27). Tuberculosis: Patients Face Difficulties With Ongoing Treatments. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/07/070724113949.htm
Public Library of Science. "Tuberculosis: Patients Face Difficulties With Ongoing Treatments." ScienceDaily. www.sciencedaily.com/releases/2007/07/070724113949.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins